587 related articles for article (PubMed ID: 34482558)
1. Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination.
Wantavornprasert K; Noppakun N; Klaewsongkram J; Rerknimitr P
Clin Exp Dermatol; 2022 Feb; 47(2):428-432. PubMed ID: 34482558
[No Abstract] [Full Text] [Related]
2. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination.
Lim PN; Wylie G
Clin Exp Dermatol; 2022 Jan; 47(1):175-176. PubMed ID: 34399001
[TBL] [Abstract][Full Text] [Related]
3. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine.
Elamin S; Hinds F; Tolland J
Clin Exp Dermatol; 2022 Jan; 47(1):153-155. PubMed ID: 34398977
[TBL] [Abstract][Full Text] [Related]
4. Another case of generalized bullous fixed drug eruption following an adenoviral vector-based COVID-19 vaccine (ChAdOx1 nCov-19).
Ben Salem C; Khelif A; Sahnoun D; Ghariani N; Sriha B; Denguezli M
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e516-e517. PubMed ID: 35274363
[No Abstract] [Full Text] [Related]
5. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients.
David R; Hanna P; Lee K; Ritchie A
Nephrology (Carlton); 2022 Jan; 27(1):109-110. PubMed ID: 34755433
[No Abstract] [Full Text] [Related]
6. Phenotypic spectrum of serious cutaneous-only adverse event following immunization with COVID-19 vaccines: a multicentre case series and literature review.
Balogun M; Millette D; Yip V; Chan SA; Lee P; Gamal N; Hashim N; Phillips D; Walsh M; Trehan P; Hanna-Bashara L; Abdullah A; Wernham A; Tso S
Clin Exp Dermatol; 2022 Mar; 47(3):614-616. PubMed ID: 34748655
[No Abstract] [Full Text] [Related]
7. Cutaneous Lymphocytic Vasculitis After Administration of the Second Dose of AZD1222 (Oxford-AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Casuality or Causality?
Ungari M; Pezzarossa E
Am J Dermatopathol; 2022 Jan; 44(1):80-82. PubMed ID: 34726187
[No Abstract] [Full Text] [Related]
8. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination.
Kreuter A; Licciardi-Fernandez MJ; Burmann SN; Burkert B; Oellig F; Michalowitz AL
Clin Exp Dermatol; 2022 Jan; 47(1):161-163. PubMed ID: 34291477
[TBL] [Abstract][Full Text] [Related]
9. Unique Case of Urticarial Skin Eruptions After COVID-19 Vaccination.
Baraldi C; Boling LB; Patrizi A; Prodi C; Deleonardi G; Gaspari V; Misciali C
Am J Dermatopathol; 2022 Mar; 44(3):198-200. PubMed ID: 34291744
[No Abstract] [Full Text] [Related]
10. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
[No Abstract] [Full Text] [Related]
11. Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination.
Ramessur R; Saffar N; Czako B; Agarwal A; Batta K
Clin Exp Dermatol; 2021 Dec; 46(8):1610-1612. PubMed ID: 34189756
[No Abstract] [Full Text] [Related]
12. Isolated thrombosis after COVID-19 vaccination: case series.
Al-Ahmad M; Al Rasheed M; Altourah L; Rodriguez-Bouza T; Shalaby N
Int J Hematol; 2022 Feb; 115(2):153-157. PubMed ID: 34993889
[TBL] [Abstract][Full Text] [Related]
13. Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine.
Hali F; Kerouach A; Alatawna H; Chiheb S; Lakhdar H
Clin Exp Dermatol; 2022 Mar; 47(3):611-613. PubMed ID: 34762342
[TBL] [Abstract][Full Text] [Related]
14. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency.
Krzywicka K; Heldner MR; Sánchez van Kammen M; van Haaps T; Hiltunen S; Silvis SM; Levi M; Kremer Hovinga JA; Jood K; Lindgren E; Tatlisumak T; Putaala J; Aguiar de Sousa D; Middeldorp S; Arnold M; Coutinho JM; Ferro JM
Eur J Neurol; 2021 Nov; 28(11):3656-3662. PubMed ID: 34293217
[TBL] [Abstract][Full Text] [Related]
15. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
16. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
17. Clinical Variant of Guillain-Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine.
Badoiu A; Moranne O; Coudray S; Ion IM
J Clin Neuromuscul Dis; 2021 Dec; 23(2):115-116. PubMed ID: 34808658
[No Abstract] [Full Text] [Related]
18. A case of interstitial lung disease following Oxford-AstraZeneca COVID-19 vaccination.
Taverner JVB; Robertson JG
Intern Med J; 2022 Jul; 52(7):1276-1277. PubMed ID: 35879232
[No Abstract] [Full Text] [Related]
19. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination.
Jiang ZH; Wong LS; Lee CH; Hsu TJ; Yu YH
Indian J Dermatol Venereol Leprol; 2022; 88(3):445. PubMed ID: 35389012
[No Abstract] [Full Text] [Related]
20. Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2.
Plüß M; Mese K; Kowallick JT; Schuster A; Tampe D; Tampe B
Front Immunol; 2021; 12():784145. PubMed ID: 35116025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
